16 results on '"Nelson, Randin"'
Search Results
2. Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis
- Author
-
Abbasi, Ahmed, Peeke, Stephen, Shah, Nishi, Mustafa, Jennat, Khatun, Fariha, Lombardo, Amanda, Abreu, Michelly, Elkind, Richard, Fehn, Karen, de Castro, Alyssa, Wang, Yanhua, Derman, Olga, Nelson, Randin, Uehlinger, Joan, Gritsman, Kira, Sica, R. Alejandro, Kornblum, Noah, Mantzaris, Ioannis, Shastri, Aditi, Janakiram, Murali, Goldfinger, Mendel, Verma, Amit, Braunschweig, Ira, and Bachier-Rodriguez, Lizamarie
- Published
- 2020
- Full Text
- View/download PDF
3. Trypanosoma cruzi infection results in an increase in intracellular cholesterol
- Author
-
Johndrow, Christopher, Nelson, Randin, Tanowitz, Herbert, Weiss, Louis M., and Nagajyothi, Fnu
- Published
- 2014
- Full Text
- View/download PDF
4. Delayed presentation of a septic transfusion reaction
- Author
-
Nelson, Randin C., Ivey, Julie R., and Eder, Anne F.
- Published
- 2017
- Full Text
- View/download PDF
5. Confirmation of Choclo Virus as the Cause of Hantavirus Cardiopulmonary Syndrome and High Serum Antibody Prevalence in Panama
- Author
-
Nelson, Randin, Cañate, Raul, Pascale, Juan Miguel, Dragoo, Jerry W., Armien, Blas, Armien, Anibal G., and Koster, Frederick
- Published
- 2010
- Full Text
- View/download PDF
6. ABO blood type association with SARS‐CoV‐2 infection mortality: A single‐center population in New York City.
- Author
-
Szymanski, James, Mohrmann, Laurel, Carter, Jamal, Nelson, Randin, Chekuri, Sweta, Assa, Andrei, Spund, Brian, Reyes‐Gil, Morayma, Uehlinger, Joan, Baron, Sarah, and Paroder, Monika
- Subjects
ABO blood group system ,SARS-CoV-2 ,PROPORTIONAL hazards models ,COVID-19 ,HOSPITAL mortality - Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has a variable clinical course with significant mortality. Early reports suggested higher rates of SARS‐CoV‐2 infection in patients with type A blood and enrichment of type A individuals among COVID‐19 mortalities. Study Design and Methods: The study includes all patients hospitalized or with an emergency department (ED) visit who were tested for SARS‐CoV‐2 between March 10, 2020 and June 8, 2020 and had a positive test result by nucleic acid test (NAT) performed on a nasopharyngeal swab specimen. A total of 4968 patients met the study inclusion criteria, with a subsequent 23.1% (n = 1146/4968) all‐cause mortality rate in the study cohort. To estimate overall risk by ABO type and account for the competing risks of in‐hospital mortality and discharge, we calculated the cumulative incidence function (CIF) for each event. Cause‐specific hazard ratios (csHRs) for in‐hospital mortality and discharge were analyzed using multivariable Cox proportional hazards models. Results: Type A blood was associated with the increased cause‐specific hazard of death among COVID‐19 patients compared to type O (HR = 1.17, 1.02–1.33, p =.02) and type B (HR = 1.32,1.10–1.58, p =.003). Conclusions: Our study shows that ABO histo‐blood group type is associated with the risk of in‐hospital death in COVID‐19 patients, warranting additional inquiry. Elucidating the mechanism behind this association may reveal insights into the susceptibility and/or immunity to SARS‐CoV‐2. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. SARS-CoV-2 PCR cycle threshold at hospital admission associated with patient mortality.
- Author
-
Choudhuri, Jui, Carter, Jamal, Nelson, Randin, Skalina, Karin, Osterbur-Badhey, Marika, Johnston, Andrew, Goldstein, Doctor, Paroder, Monika, and Szymanski, James
- Subjects
SARS-CoV-2 ,HOSPITAL admission & discharge ,HOSPITAL mortality ,ELECTRONIC health records ,POLYMERASE chain reaction - Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cycle threshold (Ct) has been suggested as an approximate measure of initial viral burden. The utility of cycle threshold, at admission, as a predictor of disease severity has not been thoroughly investigated. Methods and findings: We conducted a retrospective study of SARS-CoV-2 positive, hospitalized patients from 3/26/2020 to 8/5/2020 who had SARS-CoV-2 Ct data within 48 hours of admission (n = 1044). Only patients with complete survival data, discharged (n = 774) or died in hospital (n = 270), were included in our analysis. Laboratory, demographic, and clinical data were extracted from electronic medical records. Multivariable logistic regression was applied to examine the relationship of patient mortality with Ct values while adjusting for established risk factors. Ct was analyzed as continuous variable and subdivided into quartiles to better illustrate its relationship with outcome. Cumulative incidence curves were created to assess whether there was a survival difference in the setting of the competing risks of death versus patient discharge. Mean Ct at admission was higher for survivors (28.6, SD = 5.8) compared to non-survivors (24.8, SD = 6.0, P<0.001). In-hospital mortality significantly differed (p<0.05) by Ct quartile. After adjusting for age, gender, BMI, hypertension and diabetes, increased cycle threshold was associated with decreased odds of in-hospital mortality (0.91, CI 0.89–0.94, p<0.001). Compared to the 4
th Quartile, patients with Ct values in the 1st Quartile (Ct <22.9) and 2nd Quartile (Ct 23.0–27.3) had an adjusted odds ratio of in-hospital mortality of 3.8 and 2.6 respectively (p<0.001). The discriminative ability of Ct to predict inpatient mortality was found to be limited, possessing an area under the curve (AUC) of 0.68 (CI 0.63–0.71). Conclusion: SARS-CoV-2 Ct was found to be an independent predictor of patient mortality. However, further study is needed on how to best clinically utilize such information given the result variation due to specimen quality, phase of disease, and the limited discriminative ability of the test. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
8. 518 - Dynamics of Leukocyte Subpopulations Reconstitution Predict Infection Propensity in a Multiethnic Real World Cohort Treated with Anti-CD19 CAR-T Cell Therapy (Axicabtagene-Ciloleucel)
- Author
-
Thakkar, Astha, Cui, Zhu, Peeke, Stephen, Shah, Nishi, Lombardo, Amanda, Khatun, Fariha, DeCastro, Alyssa, Gillick, Kailyn, Joseph, Felisha, Naik, Anjali, Rahman, Shafia, D’Aiello, Angelica, Quinn, Ryann, Elkind, Richard, Sakalian, Susan, Fehn, Karen, Wright, Karen, Abreu, Michelly, Townsend-Nugent, Latoya, Chambers, Nicole, Mathew, Rosmi, Binakaj, Donika, Nelson, Randin, Palesi, Carlo, Uehlinger, Joan, Paroder, Monika, Wang, Yanhua, Shi, Yang, Zang, Xingxing, Wang, Hao, Nishimura, Christopher, Ren, Xiaoxin, Steidl, Ulrich, Derman, Olga, Janakiram, Murali, Gritsman, Kira, Kornblum, Noah, Mantzaris, Ioannis, Shastri, Aditi, Bartash, Rachel, Puius, Yoram, McCort, Margaret, Goldfinger, Mendel, Bachier-Rodriguez, Lizamarie, Verma, Amit, Braunschweig, Ira, and Sica, R.Alejandro
- Published
- 2021
- Full Text
- View/download PDF
9. Group O plasma as a media supplement for CAR-T cells and other adoptive T-cell therapies.
- Author
-
Nelson, Randin C., Fellowes, Vicki, Jin, Ping, Liu, Hui, Highfill, Steven L., Ren, Jiaqiang, Szymanski, James, Flegel, Willy A., and Stroncek, David F.
- Subjects
- *
ERYTHROCYTES , *MASS media , *CHIMERIC antigen receptors , *BLOOD cells , *PLASMA confinement , *ABO blood group system , *FLOW cytometry , *CELL culture , *IMMUNIZATION , *MONONUCLEAR leukocytes , *HLA-B27 antigen , *CULTURE media (Biology) , *BLOOD plasma , *CELL receptors , *IMMUNOLOGY technique , *RESEARCH funding , *T cells , *BLOOD - Abstract
Background: Most chimeric antigen receptor T (CAR-T) cells and other adoptive T-cell therapies (ACTs) are currently manufactured by ex vivo expansion of patient lymphocytes in culture media supplemented with human plasma from group AB donors. As lymphocytes do not express A or B antigens, the isoagglutinins of non-AB plasmas are unlikely to cause deleterious effects on lymphocytes in culture.Study Design and Methods: Seeding cultures with peripheral blood mononuclear cell (PBMNC) concentrates from group A1 donors and using a CAR-T culture protocol, parallel cultures were performed, each with unique donor plasmas as media supplements (including group O plasmas with high-titer anti-A and group AB plasmas as control). An additional variable, a 3% group A1 red blood cell (RBC) spike, was added to simulate a RBC-contaminated PBMNC collection. Cultures were monitored by cell count, viability, flow cytometric phenotype, gene expression analysis, and supernatant chemokine analysis.Results: There was no difference in lymphocyte expansion or phenotype when cultured with AB plasma or O plasma with high-titer anti-A. Compared to controls, the presence of contaminating RBCs in lymphocyte culture led to poor lymphocyte expansion and a less desirable phenotype-irrespective of the isoagglutinin titer of the plasma supplement used.Conclusions: This study suggests that ABO incompatible plasma may be used as a media supplement when culturing cell types that do not express ABO antigens-such as lymphocytes for CAR-T or other ACT. The presence of contaminating RBCs in culture was disadvantageous independent of isoagglutinin titer. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
10. How we evaluate red blood cell compatibility and transfusion support for patients with sickle cell disease undergoing hematopoietic progenitor cell transplantation.
- Author
-
Allen, Elizabeth S., Nelson, Randin C., and Flegel, Willy A.
- Subjects
- *
PROGENITOR cells , *SICKLE cell anemia , *TRANSPLANTATION of organs, tissues, etc. , *ERYTHROCYTES , *BLOOD transfusion reaction , *HEMOLYSIS & hemolysins , *ANEMIA - Abstract
Multiple hematopoietic progenitor cell (HPC) transplantation options for patients with sickle cell disease (SCD) are currently under investigation. Patients with SCD have a high rate of alloimmunization to red blood cell antigens, often complicating transfusion support. Transfusion reactions, including acute and delayed hemolytic reactions, have been observed despite immunosuppressive regimens. Allogeneic donor transplants have been shown to carry a risk of prolonged reticulocytopenia and acute hemolysis with severe anemia in nonmyeloablative regimens. We discuss our experience providing transfusion support to patients with SCD undergoing HPC transplantation, propose an outline for a complete pretransplantation evaluation, and discuss donor/recipient compatibility issues and their implications. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. Critical Value Reporting in Transfusion Medicine: A Survey of Communication Practices in US Facilities.
- Author
-
Reese, Erika M., Nelson, Randin C., Flegel, Willy A., Byrne, Karen M., and Booth, Garrett S.
- Subjects
- *
BLOOD transfusion , *BLOOD banks , *MEDICAL communication , *COMMUNICATION , *EXPERIMENTAL design , *STANDARDS - Abstract
Objectives: While critical value procedures have been adopted in most areas of the clinical laboratory, their use in transfusion medicine has not been reviewed in detail. The results of this study present a comprehensive overview of critical value reporting and communication practices in transfusion medicine in the United States.Methods: A web-based survey was developed to collect data on the prevalence of critical value procedures and practices of communicating results. The survey was distributed via email to US hospital-based blood banks.Results: Of 123 facilities surveyed, 84 (68.3%) blood banks had a critical value procedure. From a panel of 23 common blood bank results, nine results were selected by more than 70% of facilities as either a critical value or requiring rapid communication as defined by an alternate procedure.Conclusions: There was overlap among results communicated by facilities with and without a critical value procedure. The most frequently communicated results, such as incompatible crossmatch for RBC units issued uncrossmatched, delay in finding compatible blood due to a clinically significant antibody, and transfusion reaction evaluation suggestive of a serious adverse event, addressed scenarios associated with the leading reported causes of transfusion-related fatalities. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
12. Mysterious clumping in a cell therapy product.
- Author
-
Nelson, Randin, Mathews, Richard, Palesi, Carlo, Carter, Jamal, Szymanski, James, Uehlinger, Joan, Weinberg, Rona, and Paroder, Monika
- Subjects
- *
CELLULAR therapy , *BLOOD groups , *LEUCOCYTES - Abstract
The test aliquot and subsequent transplanted HPC-A aliquots thawed without issue, meeting all quality control parameters. A 73-year-old male with IgG-lambda multiple myeloma, treated with Bortezomib, Dexamethasone, and Revlimid, presented after mobilization with Filgrastim to donate hematopoietic progenitor cells by apheresis (HPC-A) in preparation for autologous stem cell transplantation.1,2 The patient's baseline coagulation tests, serum protein electrophoresis, and quantitative immunoglobulin panel were unremarkable. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
13. Bone marrow necrosis and fat embolism syndrome in sickle cell disease: A rapidly deteriorating complication.
- Author
-
Barouqa, Mohammad, Szymanski, James, Nelson, Randin, Jofre, Sebastian, and Paroder, Monika
- Subjects
SICKLE cell anemia ,OSTEONECROSIS ,BONE marrow ,EMBOLISMS ,FAT ,NECROSIS ,MOUNTAIN sickness - Abstract
B. Extensive bone marrow necrosis evident on histological sections taken from the autopsy gl Marrow sections from autopsy showed ill-defined necrotic cells with amorphous eosinophilic necrotic debris (Figure 1(B)), consistent with marrow necrosis. Bone marrow necrosis and fat embolism syndrome in sickle cell disease: Increased susceptibility of patients with non-SS genotypes and a possible association with human parvovirus B19 infection. Fat embolism syndrome secondary to bone marrow necrosis in patients with hemoglobinopathies. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
14. Chagas Heart Disease.
- Author
-
Machado, Fabiana S., Jelicks, Linda A., Kirchhoff, Louis V., Shirani, Jamshid, Nagajyothi, Fnu, Mukherjee, Shankar, Nelson, Randin, Coyle, Christina M., Spray, David C., de Carvalho, Antonio C. Campos, Guan, Fangxia, Prado, Cibele M., Lisanti, Michael P., Weiss, Louis M., Montgomery, Susan P., and Tanowitz, Herbert B.
- Published
- 2012
- Full Text
- View/download PDF
15. Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world setting.
- Author
-
Thakkar A, Cui Z, Peeke SZ, Shah N, Pradhan K, Lombardo A, Khatun F, Mustafa J, De Castro A, Gillick K, Joseph F, Naik A, Rahman S, D'Aiello A, Elkind R, Sakalian S, Fehn K, Wright K, Abreu M, Townsend-Nugent L, Chambers N, Mathew R, Binakaj D, Nelson R, Palesi C, Paroder M, Uehlinger J, Wang Y, Shi Y, Zang X, Wang H, Nishimura C, Ren X, Steidl UG, Gritsman K, Janakiram M, Kornblum N, Derman O, Mantzaris I, Shastri A, Bartash R, Puius Y, McCort M, Goldfinger M, Bachier-Rodriguez L, Verma A, Braunschweig I, and Sica RA
- Abstract
Background: Adoptive immunotherapy using CD19-targeted Chimeric antigen receptor T cells (CAR-T) has revolutionized the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Data is limited on the propensity of infections and lymphohematopoietic reconstitution after Day 30 (D30) following CAR-T cell therapy. In this study, we evaluated the prevalence and nature of infectious complications in an expanded cohort of DLBCL patients treated with CD19 CAR-T therapy and its association with the dynamics of leukocyte subpopulation reconstitution post-CAR-T cell therapy., Methods: We conducted a retrospective study including 19 patients who received axicabtagene ciloleucel and investigated associations between cytopenia and infectious complications after D30., Results: Nineteen patients were included, consisting of 42% Hispanic, 32% Caucasian, 21% African-American, and 5% Asian subjects. Post-D30 of CAR-T infusion, 47% patients (n=9) developed an infection and 53% (n=10) remained infection-free. The most common infection type observed was viral (7 patients) followed by bacterial (5 patients) and fungal (3 patients). Of 25 total infectious events, 56% were grade 1 or 2 and 44% were grade 3 with 10 being viral in etiology. To determine the kinetics of lymphohematopoietic reconstitution and its association with infection risk, we evaluated the relationship between cytopenias and rates of infection after D30. Notably, compared to non-infection group, infection group had a higher median absolute lymphocyte count (ALC) (1,000/µL vs . 600/µL, P<0.05), a lower median absolute neutrophil count (ANC)/ALC ratio (1.6 vs . 3.1, P<0.05) and a lower median AMC/ALC at D30 (0.37 vs . 1.67, P<0.05). In addition, we observed that only 22% of patients had recovered ANC >1,500/µL in the infection group as opposed to 70% in the non-infection group at D90 (P<0.05). Fifty-eight percent of the patients (11/19) with relapsed refractory DLBCL achieved a complete response with a median follow-up of 233 days (7.7 months)., Conclusions: Although CAR-T cell therapy is highly effective, infectious complications remain an important cause of morbidity and mortality. Low ANC/ALC and AMC/ALC ratios at D30 are potential novel predictors of infection and can be considered in future prophylactic strategies., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/sci-2021-008). Dr. Verma serves as an unpaid editorial board member of Stem Cell Investigation. Dr. Steidl has received research funding from GlaxoSmithKline, Bayer Healthcare, Aileron Therapeutics, Novartis, has received compensation for consultancy services and for serving on scientific advisory boards from GlaxoSmithKline, Bayer Healthcare, Novartis, Celgene, Aileron Therapeutics, Stelexis Therapeutics, Pieris Pharmaceuticals, Vor Biopharma, and Trillium Therapeutics, and has equity ownership in and is serving on the board of directors of Stelexis Therapeutics. Dr. Gritsman has received Research funding from iOnctura, SA. Dr. Shastri has received research funding from Kymera Therapeutics, consultancy fees from Guidepoint & GLG, honoraria from OncLive. Dr. Verma has received research funding from GlaxoSmithKline, BMS, Jannsen, Incyte, MedPacto, Celgene, Novartis, Curis, Prelude and Eli Lilly and Company, has received compensation as a scientific advisor to Novartis, Stelexis Therapeutics, Acceleron Pharma, and Celgene, and has equity ownership in Throws Exception and Stelexis Therapeutics. The other authors have no conflicts of interest to declare., (2021 Stem Cell Investigation. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
16. Chagas heart disease: report on recent developments.
- Author
-
Machado FS, Jelicks LA, Kirchhoff LV, Shirani J, Nagajyothi F, Mukherjee S, Nelson R, Coyle CM, Spray DC, de Carvalho AC, Guan F, Prado CM, Lisanti MP, Weiss LM, Montgomery SP, and Tanowitz HB
- Subjects
- Animals, Defibrillators, Implantable, Disease Models, Animal, Early Diagnosis, Echocardiography, Eicosanoids physiology, Endothelin-1 biosynthesis, Endothelin-1 physiology, Heart Transplantation, Humans, Life Cycle Stages, Magnetic Resonance Angiography, Mice, Pacemaker, Artificial, Rats, Stem Cell Transplantation methods, Trypanocidal Agents therapeutic use, Trypanosoma cruzi growth & development, Vasoconstriction physiology, Chagas Cardiomyopathy diagnosis, Chagas Cardiomyopathy epidemiology, Chagas Cardiomyopathy therapy
- Abstract
Chagas disease, caused by the parasite Trypanosoma cruzi, is an important cause of cardiac disease in endemic areas of Latin America. It is now being diagnosed in nonendemic areas because of immigration. Typical cardiac manifestations of Chagas disease include dilated cardiomyopathy, congestive heart failure, arrhythmias, cardioembolism, and stroke. Clinical and laboratory-based research to define the pathology resulting from T. cruzi infection has shed light on many of the cellular and molecular mechanisms leading to these manifestations. Antiparasitic treatment may not be appropriate for patients with advanced cardiac disease. Clinical management of Chagas heart disease is similar to that used for cardiomyopathies caused by other processes. Cardiac transplantation has been successfully performed in a small number of patients with Chagas heart disease.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.